OBI Pharma, Inc. (TPEX:4174)
Taiwan · Delayed Price · Currency is TWD 44.05
-1.05 (-2.33%)
Feb 11, 2026, 1:30 PM CST
OBI Pharma Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -2,361 | -2,310 | -1,046 | -1,614 | -1,531 | -1,378 |
Depreciation & Amortization | 226.16 | 216.82 | 244.86 | 240.92 | 208.75 | 214.53 |
Other Amortization | 7.12 | 5.44 | 4.1 | 5.69 | 7.52 | 17.31 |
Loss (Gain) From Sale of Assets | 0.24 | -43.32 | 0.39 | -0.01 | 15.08 | - |
Asset Writedown & Restructuring Costs | - | - | 5.96 | - | - | - |
Loss (Gain) From Sale of Investments | 0.23 | -0.26 | -879.32 | 1.02 | -0.37 | -54 |
Loss (Gain) on Equity Investments | 202.45 | 233.18 | 163.58 | - | - | - |
Stock-Based Compensation | 41.25 | 63.98 | 119.2 | 149 | 54.02 | 76.82 |
Other Operating Activities | -179.89 | -174.44 | -201.73 | -310.03 | -195.51 | -98.03 |
Change in Accounts Receivable | -2.63 | 2.28 | -4.44 | 1.43 | -2.01 | 0.07 |
Change in Inventory | -1.56 | -1.79 | -3.96 | -9.74 | -2.2 | -3.16 |
Change in Accounts Payable | 0.69 | 2.13 | -0.37 | 0.62 | 0.37 | -0.02 |
Change in Unearned Revenue | 0.44 | 1.5 | 3.13 | 3.16 | - | -77.64 |
Change in Other Net Operating Assets | 120.43 | 171.01 | -57.89 | -87.84 | -1.57 | 20.75 |
Operating Cash Flow | -1,943 | -1,834 | -1,653 | -1,620 | -1,064 | -1,609 |
Capital Expenditures | -43.94 | -113.24 | -101.93 | -254.65 | -241.33 | -182.68 |
Sale of Property, Plant & Equipment | 0.14 | 144.63 | 0.2 | 0.05 | - | - |
Cash Acquisitions | - | - | - | - | 472.65 | - |
Divestitures | - | -30.41 | -564.08 | - | - | - |
Sale (Purchase) of Intangibles | -6.75 | -6.32 | -6.23 | -45.91 | -3.86 | -2.96 |
Investment in Securities | 40.3 | 481.13 | -2,110 | 109.29 | -140 | - |
Other Investing Activities | -11.24 | 7.23 | -13.17 | 21.33 | -4.79 | -10.26 |
Investing Cash Flow | -21.5 | 483.02 | -2,795 | -169.89 | 82.68 | -195.9 |
Short-Term Debt Issued | - | 0.41 | - | 15.71 | - | 9.47 |
Long-Term Debt Issued | - | 100 | - | - | - | - |
Total Debt Issued | 146.2 | 100.41 | - | 15.71 | - | 9.47 |
Short-Term Debt Repaid | - | -4.31 | -11.4 | - | -9.47 | - |
Long-Term Debt Repaid | - | -84.44 | -51.61 | -59.31 | -58.07 | -54.6 |
Total Debt Repaid | -134.51 | -88.74 | -63.01 | -59.31 | -67.54 | -54.6 |
Net Debt Issued (Repaid) | 11.69 | 11.67 | -63.01 | -43.61 | -67.54 | -45.13 |
Issuance of Common Stock | 2,163 | 2,163 | 17.61 | 3,150 | 16.99 | 22.94 |
Other Financing Activities | 18.63 | -0 | 652.47 | 903.59 | 214.3 | 305.29 |
Financing Cash Flow | 2,194 | 2,175 | 607.07 | 4,010 | 163.75 | 283.09 |
Foreign Exchange Rate Adjustments | -6.34 | 8.4 | -0.56 | 8.53 | -8.06 | 0.54 |
Net Cash Flow | 222.75 | 832.77 | -3,842 | 2,229 | -826.12 | -1,522 |
Free Cash Flow | -1,987 | -1,947 | -1,755 | -1,874 | -1,306 | -1,792 |
Free Cash Flow Margin | -4031.85% | -3105.95% | -4223.71% | -39786.71% | -6956.13% | -1272.04% |
Free Cash Flow Per Share | -15.35 | -16.67 | -15.32 | -16.88 | -13.13 | -18.05 |
Cash Interest Paid | 12.75 | 14.65 | 3.74 | 3.99 | 3.8 | 4.18 |
Cash Income Tax Paid | - | -12.38 | -7.28 | -9.56 | -15.15 | 4.39 |
Levered Free Cash Flow | -1,168 | -1,028 | -1,228 | -1,406 | -1,002 | -770.41 |
Unlevered Free Cash Flow | -1,160 | -1,021 | -1,223 | -1,403 | -999.39 | -767.8 |
Change in Working Capital | 117.36 | 175.12 | -63.54 | -92.37 | 376.71 | -388.14 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.